Cordlife Group, a Singapore Exchange mainboard listed consumer healthcare company, and AMILI, have announced a strategic partnership to provide the first-ever gut microbiome banking service in Singapore and the region.

This partnership synergises the two company’s core specialisations - gut microbiome processing and analysis by AMILI and cryopreservation by Cordlife - to allow people in Singapore to store their gut microbiome for future faecal microbiota transplants (FMT). The gut microbiome banking service is marketed by Cordlife through its wholly owned subsidiary Cordlife Technologies.

In this collaboration, AMILI will be responsible for testing and processing of the gut microbiome obtained from clients’ stool samples before sending them to Cordlife’s facility in Singapore for longterm cryopreservation.

The foundation of this strategic partnership stems from mounting evidence suggesting that FMT is a promising approach for a myriad of diseases such as colorectal cancer, autism spectrum disorder, and even obesity. FMT or gut microbiome transplantation is the transfer of healthy microbiomes from a healthy person into the gastrointestinal tract of a sick person in order to restore microbial balance.

AMILI had set up Southeast Asia’s first and only donor stool bank in 2019 in Singapore, giving patients access to gut microbiome samples from healthy donors. Since then, AMILI has provided samples to patients in Singapore, Malaysia, and Thailand who need gut microbiome transplants (GMT).